---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product comparison"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product comparison. Topics: APOL1-directed and other investigational therapies for AMKD: review table; MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results; MZE829: HORIZON enrollment completed and pivotal trial planned for the first half of 2027; MZE829: HORIZON registry record; 6 further topics. 10 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/product-comparison"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### APOL1-directed and other investigational therapies for AMKD: review table

| Trial | Therapeutic | Phase | Mechanism studied |
| --- | --- | --- | --- |
| AMPLITUDE | “Inaxaplin” | “Phase 3” | “APOL1 channel function inhibition” |
| JUSTICE | “Baricitinib” | “Phase 2” | “Janus kinase STAT pathway” |
| NCT04269031 | “AZD2373” | “Phase 1” | “Antisense oligonucleotide therapy to reduce APOL1 mRNA formation” |
| NCT05324410 | “VX-840” | “Phase 1” | “APOL1 channel blocker” |
| Not named | “MZE829” | “Phase 1” | “APOL1 small molecule inhibitor” |

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

> “Antisense oligonucleotide therapy is in phase 1 trials because of studies in mice showing a dose-dependent reduction in liver and kidney APOL1 mRNA.”
> “a recent small molecule inhibitor, MZE829, attempts to phenocopy this protective variant in a phase 1 study.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

<a id="topic-2.1.2.14-2"></a>

### MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results

> “today announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).”
> “The HORIZON study is a Phase 2, open-label basket design trial that enrolled patients with broad AMKD carrying the APOL1 high risk genotype, including diabetic and non-diabetic patients and non-diabetic patients with severe focal segmental glomerulosclerosis (FSGS).”
> “For this topline analysis, 15 patients were enrolled in the HORIZON study and all were included in a safety and tolerability analysis. Twelve patients were evaluated for efficacy, i.e., uACR reduction, based on meeting the per protocol compliance threshold.”
> “Across all evaluated patients, a mean reduction in proteinuria from baseline of 35.6% was observed and 50% of patients achieved at least a 30% reduction in uACR.”
> “In FSGS patients, treatment with MZE829 led to a mean reduction in uACR of 61.8%. In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%. In patients with AMKD with diabetes, five patients were evaluable per protocol for efficacy, with two patients achieving at least a 30% reduction in uACR.”
> “No serious adverse events (AEs) or severe treatment-related adverse events (TRAEs) were observed.”

Source: [Maze Therapeutics press release, MZE829 phase 2 topline data (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-announces-positive-topline-data-phase-2)

<a id="topic-2.1.2.14-3"></a>

### MZE829: HORIZON enrollment completed and pivotal trial planned for the first half of 2027

> “Enrollment for the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients in a broad AMKD population is complete and exceeded the target enrollment range of 10-15 patients per cohort as previously guided.”
> “In early 2027, Maze expects to announce the final data from HORIZON which is designed to evaluate the potential of MZE829 to treat each of three AMKD patient subgroups: AMKD without diabetes, AMKD with diabetes and AMKD with focal segmental glomerulosclerosis (FSGS).”
> “Subject to regulatory feedback, Maze plans to initiate a pivotal trial in the first half of 2027.”

Source: [Maze Therapeutics third quarter 2026 results (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.2.14-4"></a>

### MZE829: HORIZON registry record

> “An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.”

Source: [ClinicalTrials.gov NCT06830629](https://clinicaltrials.gov/study/NCT06830629)

<a id="topic-2.1.2.14-5"></a>

### Competitive positioning of inaxaplin and MZE829

> “Inaxaplin, a small-molecule inhibitor of APOL1 channel function, could compete with Maze Therapeutics’ MZE829.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

<a id="topic-2.1.2.14-6"></a>

### AZD2373 (AstraZeneca): subcutaneous APOL1-directed therapy, phase 2b APPRECIATE trial

> “The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.”
> “Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo.”

Source: [ClinicalTrials.gov NCT06824987](https://clinicaltrials.gov/study/NCT06824987)

| Field | Quoted record |
| --- | --- |
| Sponsor | “AstraZeneca” |
| Status | “Active, not recruiting” |
| Enrollment (actual) | “63” |
| Primary completion (estimated) | “2027-10-04” |

Source: [ClinicalTrials.gov NCT06824987](https://clinicaltrials.gov/study/NCT06824987)

<a id="topic-2.1.2.14-7"></a>

### AZD2373: APOL1 genotyping clinical trial assay used to select participants

> “The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).”

Source: [ClinicalTrials.gov NCT06839833](https://clinicaltrials.gov/study/NCT06839833)

<a id="topic-2.1.2.14-8"></a>

### AZD2373: phase 1 studies in healthy participants of African ancestry

> “following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.”

Source: [ClinicalTrials.gov NCT04269031](https://clinicaltrials.gov/study/NCT04269031)

> “following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of sub-Saharan West African ancestry.”

Source: [ClinicalTrials.gov NCT05351047](https://clinicaltrials.gov/study/NCT05351047)

<a id="topic-2.1.2.14-9"></a>

### VX-840 and other Vertex APOL1 inhibitors

> “The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.”

Source: [ClinicalTrials.gov NCT05324410](https://clinicaltrials.gov/study/NCT05324410)

> “Consistent with the company’s serial innovation strategy, Vertex will also continue to investigate additional small molecule APOL1 inhibitors in the clinic.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.2.14-10"></a>

### Approved therapies directed at the cause of AMKD

> “There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

Additional sources: [Limb et al. (2024)](https://doi.org/10.1681/ASN.2024mr2v3twq); [Hopper et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42480070/); [Dogra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42709370/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
